Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Termination" from the Phase 3 Study B7841005. Approximately 145 adolescent and adult participants 12 to <75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as

  • 0 views
  • 10 Aug, 2022
  • 14 locations
Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV

severe haemophilia a
antihemophilic factor
Factor VIII
gene therapy
hemophilia
  • 238 views
  • 05 May, 2022
  • 43 locations
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once …

severe haemophilia a
treatment regimen
antihemophilic factor
Factor VIII
acute hemorrhage
  • 130 views
  • 11 Aug, 2022
  • 56 locations
Personalized Medicine for Canadians With Hemophilia (PMCH)

Performing an individual pharmacokinetic (PK) estimate is only the first step in implementing tailored prophylaxis, which requires using the PK profile information to design a personalized treatment regimen matching the treatment needs of individual patients. The overarching goal of WAPPS-Hemo is to provide an easy-to-use web application supporting all the …

treatment regimen
severe haemophilia a
hemophilia
  • 4 views
  • 01 Mar, 2022
  • 5 locations
A Gene Transfer Study for Hemophilia A

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.

antihemophilic factor
cryoprecipitate
  • 842 views
  • 29 Jul, 2022
  • 15 locations
Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Study of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a

  • 0 views
  • 22 Mar, 2022
  • 1 location
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

This is a multi-center, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of BBM-H901 injection in Hemophilia B subjects with ≤2

  • 0 views
  • 08 Aug, 2022
  • 7 locations
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Long-term safety and efficacy follow-up for participants with Hemophilia B who were previously treated in the C0371005 (formerly SPK-9001-101) study, and a dose-escalation sub-study evaluating

hemophilia
  • 146 views
  • 21 Jul, 2022
  • 3 locations
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B (Paradigm9)

The study investigates how well the medicine called nonacog beta pegol (N9-GP) works in Chinese people with haemophilia B. Participants will be treated with N9-GP. This is a medicine that

  • 0 views
  • 08 Jul, 2022
  • 2 locations
Validation and Reliability of the CHO-KLAT in Turkish

The aim of this study is to investigate the Turkish validity and reliability of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool version2.0. Patients aged 4-18 years with hemophilia a or b will be included in the study. The study was planned as a multicenter and it is aimed to reach …

  • 0 views
  • 09 Jul, 2022
  • 3 locations